|
| |
 |
|
 |
|
|
EU-FP7: EUTRAF - The European Network for Translational Research in Atrial Fibrillation
|
|
|
|
|
|
PROJEKT: The "European Network for translational research in atrial fibrillation" (EUTRAF) was granted a total amount of 12 million euros for integrated research in order to explore disease mechanisms and to develop better diagnostic means and new therapies in patients with atrial fibrillation. The total funding period of this network is 5 years.
|
|
The initiation and perpetuation of atrial fibrillation (AF) can be regarded as a complication of a progressive transformation of the structure and functional properties of the atria. This transformation is the result of complex and multiple changes at the molecular, cellular and organ levels which interact to form the basis for proarrhythmic mechanisms in AF. Numerous individual and environmental factors are probably involved in this profound transformation process in the atria. Therefore, we believe that progress in the diagnostics, prevention and treatment of AF requires highly integrative research from the molecule to bedside and from specific signaling pathways and electrophysiological mechanisms to population based studies.
A consortium was formed providing this variety of expertises and has identified central research objectives for improvements in AF prevention and therapy. In 5 work packages focusing on basic research, new biomarkers for AF and therapeutic targets will be identified. We will study mechanisms of conduction disturbances in the atria, explore new ion channel targets for treatment of AF, identify specific alterations in the atria depending on the underlying heart disease, and evaluate beneficial effects of organ-protective compounds.
Within two clinically oriented work packages the clinical application of these findings will be tested. The predictive value of diagnostic tools like serum biomarkers, 3D reconstruction of atrial conduction patterns based on high resolution body surface ECGs, and echo-cardiographic markers will be studied in large scale population studies. The new therapeutic targets will be explored in smaller prove-of-principle clinical trials (substrate oriented ablation, new pharmacological targets, and local gene delivery).
Homepage: http://www.eutraf.eu/
Coordinator:
ST GEORGE'S HOSPITAL MEDICAL SCHOOL (UNITED KINGDOM)
Participants:
CHU HOPITAUX DE BORDEAUX (FRANCE)
OSYPKA AG (GERMANY)
ERKEM TIBBI YAYINCILIK YAZILIM GELISTIRME VE EGITIM HIZMETLERI LIMITED SIRKETI (TURKEY)
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG (GERMANY)
SANOFIS AVENTIS DEUTSCHLAND GMBH (GERMANY)
PHILIPPS UNIVERSITAET MARBURG (GERMANY)
UNIVERSITAET BERN (SWITZERLAND)
MEDIZINISCHE UNIVERSITAET GRAZ (AUSTRIA)
OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG (GERMANY)
ERNST-MORITZ-ARNDT-UNIVERSITÄT GREIFSWALD (GERMANY)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UNITED KINGDOM)
UNIVERSITEIT MAASTRICHT (NETHERLANDS)
THE UK HEALTH & ENVIRONMENT RESEARCH INSTITUTE (UNITED KINGDOM)
UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (FRANCE)
TECHNISCHE UNIVERSITAET DRESDEN (GERMANY)
XENTION LTD (UNITED KINGDOM)
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (GERMANY)
Project details
Project Acronym: EUTRAF
Project Reference: 261057
Start Date: 2010-11-01
Duration: 60 months
Project Cost: 15.71 million euro
Contract Type: Large-scale integrating project
End Date: 2015-10-31
Project Status: Execution
Project Funding: 12 million euro
Source: Cordis, http://www.eutraf.eu/
Kontakt:
Prof. Dr. rer. nat. habil. Uwe Lendeckel
Tel: +49 03834/865425
eMail: uwe.lendeckel [at] uni-greifswald.de
Universitätsmedizin Greifswald
Körperschaft des öffentlichen Rechts
Institut für Medizinische Biochemie und Molekularbiologie
Fleischmannstraße 42-44
17475 Greifswald
|
|
|
|
|
|
|
|
|
|
Öffentlich finanzierte Forschungsprojekte 
für Projekte
uni-greifswald.de
